Green light for 77 new medicines in the EU in 2023
A total of seventy-seven new medicinal products were approved in Europe last year, seven of which were given the green light in December. At European level, the EMA’s… read more.
A total of seventy-seven new medicinal products were approved in Europe last year, seven of which were given the green light in December. At European level, the EMA’s… read more.
For people with hearing loss, the risk of death is lower among those who regularly use a hearing aid, researchers reported on Jan. 3, 2024 in The Lancet… read more.
Your weekly digest of the top healthcare stories, covering news published from 01/01/2024 – 05/01/2024. The Daily Telegraph The rate of cancer diagnosis in Britain will reach one… read more.
Researchers from a Taiwanese study report that an increase in the risk of miscarriage is associated with benzodiazepine use during pregnancy, after adjustments for cofounders. The findings appeared… read more.
ASHP Midyear Clinical Meeting – Highlights Antimicrobial resistance (AMR) caused an estimated five million deaths in 2019 and by 2050 this is likely to rise to 10 million… read more.
Less than half of patients with malignant ureteral obstruction (MUO) – a serious complication of advanced cancer, with a poor prognosis – receive palliative care (PC) for their… read more.
A non-prescription drug abuse crisis in Japan seems only one overdose away. The demand for a particular anti-cough drug has been rising, along with the social impact of… read more.
Esperion announced that the FDA has approved an updated LDL-cholesterol lowering indication for Nexletol and Nexlizet to include the treatment of primary hyperlipidemia as a qualifier for existing… read more.
Octapharma USA announced the expansion of the FDA approval for wilate, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection. The approved label… read more.
Kite, a Gilead Company announced data from follow-up analyses of three studies of Yescarta (axicabtagene ciloleucel) that demonstrate the long-term survival potential for patients living with several sub-types… read more.
Theratechnologies Inc. announced that the FDA has approved the company’s Labelling Prior Approval Supplement to include a 2000-mg intravenous (IV) push loading dose for Trogarzo (ibalizumab-uiyk). IV push… read more.
Merck Inc., known as MSD outside of the United States and Canada, announced that the FDA has issued a Complete Response Letter (CRL) regarding Merck’s New Drug Application… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.